Loading…
Reported covered position: Chief of Staff, Rep. Linda Sanchez Chief of Staff, Rep. Patrick Kennedy Communications staff, House Minority Leader Richard Gephardt
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Health Care Reform -The Improving Chronic Care Management Act (H.R. 3436) Biosimilars Policy (no Bill). Affordable and Safe Prescription Drug Importation Act;H.R. 987 - Strengthening Health Care and Lowering Prescription Drug Costs Act Prescription Pricing for People Act (S. 1227/H.R. 2376) Drug Rebate regulation - (proposed rule, no Bill) Newborn Screening Programs (no Bill) Scientific and Medical Innovation (no bill) Affordable Prescriptions for Patients Act of S.1416
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
Changes in the Medicare Part B reimbursement system; International Pricing Index proposal; and Administration and Congressional proposal to address rebates in the Medicare Part D program.
Issues pertaining to the U.S. Patent system; Inter Partes Review process at the PTO; Patent law as it pertains to the IP system/process.
Source: Senate LDA
Health Care Reform -The Improving Chronic Care Management Act (H.R. 3436) Biosimilars Policy (no Bill). Affordable and Safe Prescription Drug Importation Act;H.R. 987 - Strengthening Health Care and Lowering Prescription Drug Costs Act Prescription Pricing for People Act (S. 1227/H.R. 2376) Drug Rebate regulation - (proposed rule, no Bill) Newborn Screening Programs (no Bill) Scientific and Medical Innovation (no bill) Affordable Prescriptions for Patients Act of S.1416
Strengthening Health Care and Lowering Prescription Drug Costs Act
Health Care Reform -The Improving Chronic Care Management Act (H.R. 3436) Biosimilars Policy (no Bill). Affordable and Safe Prescription Drug Importation Act;H.R. 987 - Strengthening Health Care and Lowering Prescription Drug Costs Act Prescription Pricing for People Act (S. 1227/H.R. 2376) Drug Rebate regulation - (proposed rule, no Bill) Newborn Screening Programs (no Bill) Scientific and Medical Innovation (no bill) Affordable Prescriptions for Patients Act of S.1416
Health Care Reform -The Improving Chronic Care Management Act (H.R. 3436) Biosimilars Policy (no Bill). Affordable and Safe Prescription Drug Importation Act;H.R. 987 - Strengthening Health Care and Lowering Prescription Drug Costs Act Prescription Pricing for People Act (S. 1227/H.R. 2376) Drug Rebate regulation - (proposed rule, no Bill) Newborn Screening Programs (no Bill) Scientific and Medical Innovation (no bill) Affordable Prescriptions for Patients Act of S.1416
Health Care Reform -The Improving Chronic Care Management Act (H.R. 3436) Biosimilars Policy (no Bill). Affordable and Safe Prescription Drug Importation Act;H.R. 987 - Strengthening Health Care and Lowering Prescription Drug Costs Act Prescription Pricing for People Act (S. 1227/H.R. 2376) Drug Rebate regulation - (proposed rule, no Bill) Newborn Screening Programs (no Bill) Scientific and Medical Innovation (no bill) Affordable Prescriptions for Patients Act of S.1416
1) Innovation Act (H.R. 9) and the Patent Transparency and Improvements Act promoting appropriate rules for discovery and pleadings in patent cases for both drugs and biologics; and 2) support changes to Inter Partes Review process within the Patent & Trademark Office.
1) Innovation Act (H.R. 9) and the Patent Transparency and Improvements Act promoting appropriate rules for discovery and pleadings in patent cases for both drugs and biologics; and 2) support changes to Inter Partes Review process within the Patent & Trademark Office.
1) Innovation Act (H.R. 9) and the Patent Transparency and Improvements Act promoting appropriate rules for discovery and pleadings in patent cases for both drugs and biologics; and 2) support changes to Inter Partes Review process within the Patent & Trademark Office.
1) Innovation Act (H.R. 9) and the Patent Transparency and Improvements Act promoting appropriate rules for discovery and pleadings in patent cases for both drugs and biologics; and 2) support changes to Inter Partes Review process within the Patent & Trademark Office.
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges; 4) support efforts to modernize FDA processes in the 21st Century Cures initiative; and 5) Opposition to the Medical Innovation Act (S. 320/H.R. 744).
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges; 4) support efforts to modernize FDA processes in the 21st Century Cures initiative; and 5) Opposition to the Medical Innovation Act (S. 320/H.R. 744).
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges; 4) support efforts to modernize FDA processes in the 21st Century Cures initiative; and 5) Opposition to the Medical Innovation Act (S. 320/H.R. 744).
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges; 4) support efforts to modernize FDA processes in the 21st Century Cures initiative; and 5) Opposition to the Medical Innovation Act (S. 320/H.R. 744).
1) Innovation Act (H.R. 9) and the Patent Transparency and Improvements Act promoting appropriate rules for discovery and pleadings in patent cases for both drugs and biologics; and 2) support changes to Inter Partes Review process within the Patent & Trademark Office.
1) Innovation Act (H.R. 9) and the Patent Transparency and Improvements Act promoting appropriate rules for discovery and pleadings in patent cases for both drugs and biologics; and 2) support changes to Inter Partes Review process within the Patent & Trademark Office.
1) Innovation Act (H.R. 9) and the Patent Transparency and Improvements Act promoting appropriate rules for discovery and pleadings in patent cases for both drugs and biologics; and 2) support changes to Inter Partes Review process within the Patent & Trademark Office.
1) Innovation Act (H.R. 9) and the Patent Transparency and Improvements Act promoting appropriate rules for discovery and pleadings in patent cases for both drugs and biologics; and 2) support changes to Inter Partes Review process within the Patent & Trademark Office.
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges; 4) support efforts to modernize FDA processes in the 21st Century Cures initiative; and 5) Opposition to the Medical Innovation Act (S. 320/H.R. 744).
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges; 4) support efforts to modernize FDA processes in the 21st Century Cures initiative; and 5) Opposition to the Medical Innovation Act (S. 320/H.R. 744).
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges; 4) support efforts to modernize FDA processes in the 21st Century Cures initiative; and 5) Opposition to the Medical Innovation Act (S. 320/H.R. 744).
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges; 4) support efforts to modernize FDA processes in the 21st Century Cures initiative; and 5) Opposition to the Medical Innovation Act (S. 320/H.R. 744).
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; and 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges.
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; and 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges.
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; and 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges.
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; and 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges.
Patent legislation H.R. 3309 and S. 1720 promoting appropriate rules for discovery in patent cases for both drugs and biologics.
Health Care Reform -The Improving Chronic Care Management Act (H.R. 3436) Biosimilars Policy (no Bill). Affordable and Safe Prescription Drug Importation Act;H.R. 987 - Strengthening Health Care and Lowering Prescription Drug Costs Act Prescription Pricing for People Act (S. 1227/H.R. 2376) Drug Rebate regulation - (proposed rule, no Bill) Newborn Screening Programs (no Bill) Scientific and Medical Innovation (no bill) Affordable Prescriptions for Patients Act of S.1416
IP protections for biologics and pharmaceuticals, consistent with U.S. law, to be included in trade agreements.
Domestic and international tax policies that protect and incentivize U.S. based research and manufacturing jobs.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
1) Support increased funding for federal newborn screening programs; 2) Support policies that encourage scientific and medical innovation; and 3) Support policies that encourage the uptake of a strong biosimilars market in the U.S.
Support strong IP protections for biologics and pharmaceuticals, consistent with U.S. law, to be included in trade agreements.
1) Preserve current protections within the U.S. Patent system; 2) Support changes to the Inter Partes Review process at the PTO; 3) Support changes in patent law that discourage or prevent "gaming" of the IP system/process.
1) Opposition to changes in the Medicare Part B reimbursement system; 2) Opposition to the International Pricing Index proposal; and 3) Support for administration's proposal to address rebates in the Medicare Part D program.
Support domestic and international tax policies that protect and incentivize U.S. based research and manufacturing jobs.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
1) Opposition to price controls in the Medicare Part D program; and 2) Opposition to changes in the Medicare Part B reimbursement system.
1) Support 340B anti-fraud and program integrity policies; 2) Support policies and increased funding to improve federal Newborn Screening Programs; and 3) Support policies that support and preserve scientific and medical innovation.
Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in trade agreements.
Support domestic and international tax policies which protect and incentivize US-based research and manufacturing jobs.
Preserve current protections within U.S. Patent system and support changes to the Inter Partes Review within the Patent & Trademark Office.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Support domestic and international tax policies which protect and incentivize US-based research and manufacturing jobs.
Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in trade agreements.
1) Opposition to rebates and price controls in the Medicare Part D program; and 2) Opposition to changes in the Medicare Part B reimbursement system.
Preserve current protections within U.S. Patent system and support changes to the Inter Partes Review within the Patent & Trademark Office.
1) Support 340B anti-fraud and program integrity policies; 2) Support policies and increased funding to improve federal Newborn Screening Programs; and 3) Support policies that support and preserve scientific and medical innovation.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Preserve current protections within U.S. Patent system and support changes to the Inter Partes Review within the Patent & Trademark Office.
Support domestic and international tax policies which protect and incentivize US-based research and manufacturing jobs.
1) Opposition to rebates and price controls in the Medicare Part D program; and 2) Opposition to changes in the Medicare Part B reimbursement system.
Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in trade agreements.
1) Support 340B anti-fraud and program integrity policies; 2) Support policies and increased funding to improve federal Newborn Screening Programs; and 3) Support policies that support and preserve scientific and medical innovation.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Preserve current protections within U.S. Patent system and support changes to the Inter Partes Review within the Patent & Trademark Office.
Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in trade agreements.
1) Opposition to rebates and price controls in the Medicare Part D program; and 2) Opposition to changes in the Medicare Part B reimbursement system.
Support domestic and international tax policies which protect and incentivize US-based research and manufacturing jobs.
Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the US-EU (TTIP) trade agreement.
1) Opposition to rebates and price controls in the Medicare Part D program; and 2) Opposition to changes in the Medicare Part B reimbursement system.
1) Opposition to rebates and price controls in the Medicare Part D program; and 2) Opposition to changes in the Medicare Part B reimbursement system.
Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the US-EU (TTIP) trade agreement.
1) Support 340B anti-fraud and program integrity policies; 2) Support policies and increased funding to improve federal Newborn Screening Programs; and 3) Support policies that support and preserve scientific and medical innovation.
Support domestic and international tax policies which protect and incentivize US-based research and manufacturing jobs.
Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the US-EU (TTIP) trade agreement.
Preserve current protections within U.S. Patent system and support changes to the Inter Partes Review within the Patent & Trademark Office.
Support domestic and international tax policies which protect and incentivize US-based research and manufacturing jobs.
Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the US-EU (TTIP) trade agreement.
1) Opposition to rebates and price controls in the Medicare Part D program; and 2) Opposition to changes in the Medicare Part B reimbursement system.
1) Opposition to rebates and price controls in the Medicare Part D program; and 2) Opposition to changes in the Medicare Part B reimbursement system.
1) Support 340B anti-fraud and program integrity policies; 2) support efforts to modernize FDA processes in the 21st Century Cures Act and the Senate Innovations for Healthier Americans initiative; 3) Support policies that encourage and preserve scientific and medical innovation; and 4) Support increased funding for federal newborn screening programs.
1) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans-Pacific Partnership (TPP) trade agreement; and 2) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the US-EU (TTIP) trade agreement.
1) Support domestic and international tax policies which protect and incentivize US-based research and manufacturing jobs.
1) Support 340B anti-fraud and program integrity policies; 2) support efforts to modernize FDA processes in the 21st Century Cures Act and the Senate Innovations for Healthier Americans initiative; 3) Support policies that encourage and preserve scientific and medical innovation; and 4) Support increased funding for federal newborn screening programs.
1) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans-Pacific Partnership (TPP) trade agreement; and 2) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the US-EU (TTIP) trade agreement.
1) Support domestic and international tax policies which protect and incentivize US-based research and manufacturing jobs.
1) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans-Pacific Partnership (TPP) trade agreement; and 2) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the US-EU (TTIP) trade agreement.
1) Support 340B anti-fraud and program integrity policies; 2) support efforts to modernize FDA processes in the 21st Century Cures Act and the Senate Innovations for Healthier Americans initiative; 3) Support policies that encourage and preserve scientific and medical innovation; and 4) Support increased funding for federal newborn screening programs.
1) Support 340B anti-fraud and program integrity policies; 2) support efforts to modernize FDA processes in the 21st Century Cures Act and the Senate Innovations for Healthier Americans initiative; and 3) Support policies that encourage and preserve scientific and medical innovation.
1) Innovation Act (H.R. 9) and the Patent Transparency and Improvements Act promoting appropriate rules for discovery and pleadings in patent cases for both drugs and biologics; and 2) support changes to Inter Partes Review process within the Patent & Trademark Office.
1) Support domestic and international tax policies which protect and incentivize US-based research and manufacturing jobs.
1) Innovation Act (H.R. 9) and the Patent Transparency and Improvements Act promoting appropriate rules for discovery and pleadings in patent cases for both drugs and biologics; and 2) support changes to Inter Partes Review process within the Patent & Trademark Office.
1) Support domestic and international tax policies which protect and incentivize US-based research and manufacturing jobs.
1) Support 340B anti-fraud and program integrity policies; 2) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges; 3) support efforts to modernize FDA processes in the 21st Century Cures Act and the Senate Innovations for Healthier Americans initiative; and 4) Support policies that encourage and preserve scientific and medical innovation.
1) Innovation Act (H.R. 9) and the Patent Transparency and Improvements Act promoting appropriate rules for discovery and pleadings in patent cases for both drugs and biologics; and 2) support changes to Inter Partes Review process within the Patent & Trademark Office.
1) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans-Pacific Partnership (TPP) trade agreement; and 2) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the US-EU (TTIP) trade agreement.
1) Support 340B anti-fraud and program integrity policies; 2) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges; 3) support efforts to modernize FDA processes in the 21st Century Cures initiative; and 4) Support policies that encourage and preserve scientific and medical innovation.
1) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans-Pacific Partnership (TPP) trade agreement; and 2) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the US-EU (TTIP) trade agreement.
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges; 4) support efforts to modernize FDA processes in the 21st Century Cures initiative; and 5) Opposition to the Medical Innovation Act (S. 320/H.R. 744).
1) Innovation Act (H.R. 9) and the Patent Transparency and Improvements Act promoting appropriate rules for discovery and pleadings in patent cases for both drugs and biologics; and 2) support changes to Inter Partes Review process within the Patent & Trademark Office.
1) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans-Pacific Partnership (TPP) trade agreement; and 2) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the US-EU (TTIP) trade agreement.
Patent legislation H.R. 3309 and S. 1720 promoting appropriate rules for discovery in patent cases for both drugs and biologics.
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; and 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges.
1) Support domestic and international tax policies which protect and incentivize US-based research and manufacturing jobs; Support maintaining the orphan drug tax credit; and 3) Support maintaining and making permanent the Research & Development tax credit.
1) Support domestic and international tax policies which protect and incentivize US-based research and manufacturing jobs; 2) Support maintaining the orphan drug tax credit; and 3) Support maintaining and making permanent the Research & Development tax credit.
1) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans-Pacific Partnership (TPP) trade agreement; and 2) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the US-EU (TTIP) trade agreement.
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; and 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges.
1) Support 340B anti-fraud and program integrity policies; 2) Support policies and increased funding to improve federal Newborn Screening Programs; and 3) Support policies that support and preserve scientific and medical innovation.
Support domestic and international tax policies which protect and incentivize US-based research and manufacturing jobs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Preserve current protections within U.S. Patent system and support changes to the Inter Partes Review within the Patent & Trademark Office.
1) Support 340B anti-fraud and program integrity policies; 2) Support policies and increased funding to improve federal Newborn Screening Programs; and 3) Support policies that support and preserve scientific and medical innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Preserve current protections within U.S. Patent system and support changes to the Inter Partes Review within the Patent & Trademark Office.
Support domestic and international tax policies which protect and incentivize US-based research and manufacturing jobs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
1) Opposition to rebates and price controls in the Medicare Part D program; and 2) Opposition to changes in the Medicare Part B reimbursement system.
1) Support 340B anti-fraud and program integrity policies; 2) Support policies and increased funding to improve National Newborn Screening Program; and 3) Support policies that support and preserve scientific and medical innovation.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
1) Support 340B anti-fraud and program integrity policies; 2) Support policies and increased funding to improve National Newborn Screening Program; and 3) Support policies that support and preserve scientific and medical innovation.
Support changes to the Inter Partes Review within the Patent & Trademark Office.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
1) Innovation Act (H.R. 9) and the Patent Transparency and Improvements Act promoting appropriate rules for discovery and pleadings in patent cases for both drugs and biologics; and 2) support changes to Inter Partes Review process within the Patent & Trademark Office.
1) Support domestic and international tax policies which protect and incentivize US-based research and manufacturing jobs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
1) Opposition to rebates and price controls in the Medicare Part D program; and 2) Opposition to changes in the Medicare Part B reimbursement system.
1) Innovation Act (H.R. 9) and the Patent Transparency and Improvements Act promoting appropriate rules for discovery and pleadings in patent cases for both drugs and biologics; and 2) support changes to Inter Partes Review process within the Patent & Trademark Office.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
1) Innovation Act (H.R. 9) and the Patent Transparency and Improvements Act promoting appropriate rules for discovery and pleadings in patent cases for both drugs and biologics; and 2) support changes to Inter Partes Review process within the Patent & Trademark Office.
1) Opposition to rebates and price controls in the Medicare Part D program; and 2) Opposition to changes in the Medicare Part B reimbursement system.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
1) Opposition to rebates and price controls in the Medicare Part D program; and 2) Opposition to changes in the Medicare Part B reimbursement system.
1) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans-Pacific Partnership (TPP) trade agreement; and 2) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the US-EU (TTIP) trade agreement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
1) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans-Pacific Partnership (TPP) trade agreement; and 2) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the US-EU (TTIP) trade agreement.
1) Opposition to rebates and price controls in the Medicare Part D program; and 2) Opposition to changes in the Medicare Part B reimbursement system.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
1) Support domestic and international tax policies which protect and incentivize US-based research and manufacturing jobs.
1) Opposition to rebates and price controls in the Medicare Part D program; and 2) Opposition to changes in the Medicare Part B reimbursement system.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
1) Opposition to rebates price controls in the Medicare Part D program; and 2) Opposition to changes in the Medicare Part B reimbursement system.
1) Innovation Act (H.R. 9) and the Patent Transparency and Improvements Act promoting appropriate rules for discovery and pleadings in patent cases for both drugs and biologics; and 2) support changes to Inter Partes Review process within the Patent & Trademark Office.
1) Support domestic and international tax policies which protect and incentivize US-based research and manufacturing jobs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
1) Support domestic and international tax policies which protect and incentivize US-based research and manufacturing jobs.
1) Support 340B anti-fraud and program integrity policies; 2) Support policies to improve National Newborn Screening Program, including H.R. 1281 and S. 1417; 3) ACA implementation oversight to protect patient access to medical specialists in new health care insurance exchanges; 4) support efforts to modernize FDA processes in the 21st Century Cures initiative; and 5) Opposition to the Medical Innovation Act (S. 320/H.R. 744).
1) Opposition to rebates price controls in the Medicare Part D program; and 2) Opposition to changes in the Medicare Part B reimbursement system.
Filing targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
1) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans-Pacific Partnership (TPP) trade agreement; and 2) Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the US-EU (TTIP) trade agreement.
1) Opposition to rebates price controls in the Medicare Part D program; and 2) Opposition to changes in the Medicare Part B reimbursement system.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE